Clinical Takeaway
Clinical trials show that cannabis-based products, particularly those with higher THC content, provide modest reductions in chronic pain compared to placebo, though the overall strength of evidence remains low to moderate. Benefits must be weighed against well-documented harms including dizziness, cognitive effects, and psychoactive side effects. Patients and clinicians should interpret these findings cautiously and individualize treatment decisions based on pain type, product formulation, and patient risk profile.
#1 Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Citation: Chou Roger et al.. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.. Annals of internal medicine. 2026. PMID: 41429020.
Design: 5 Journal: 3 N: 4 Recency: 3 Pop: 2 Human: 1 Risk: -2
This systematic review addresses a critical evidence gap regarding cannabinoid efficacy and safety in chronic pain management, where current clinical guidance remains limited by heterogeneous trial quality and incomplete harm characterization. By stratifying cannabinoids according to THC:CBD ratios, the analysis enables clinicians to make more informed pharmacological decisions and identify which formulations may offer favorable risk-benefit profiles for specific patient populations. Given the expanding legal availability of cannabis-based products and increasing patient demand, this updated synthesis provides essential evidence to support evidence-based prescribing practices and inform clinical decision-making in pain management.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: 25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S
💊 This updated systematic review provides timely evidence on cannabinoid efficacy for chronic pain, though practitioners should recognize that heterogeneity in study design, product formulation, and THC-to-CBD ratios significantly limits direct comparison and generalizability to real-world patients. The inclusion of only randomized placebo-controlled trials strengthens internal validity but may not capture longer-term outcomes or the preferences and responses of patients in actual clinical practice, where dosing titration and product selection are highly individualized. Notably, this analysis focuses on pain efficacy without detailed examination of cognitive, psychiatric, or dependency-related harms, which remain important considerations in patient counseling and monitoring. When discussing cannabinoid options with patients experiencing inadequate relief from conventional analgesics, clinicians should use these findings to have evidence-informed conversations while acknowledging that optimal THC-to-CBD ratios and dosing schedules remain largely empirical and patient-specific. A pragmatic approach involves starting with lower THC formulations, documenting pain and